The Trump administration is pressing pharmaceutical companies to begin negotiations aimed at aligning U.S. drug prices with those of comparable economies, which are generally lower. The Department of Health and Human Services expressed urgency for the companies to cease obstructions impeding progress in reducing drug costs for Americans. However, further clarifications on which drugs and pricing targets will be negotiated remain pending as industry executives await regulatory guidance.